{"id":69625,"date":"2026-07-08T15:05:18","date_gmt":"2026-07-08T07:05:18","guid":{"rendered":"https:\/\/flcube.com\/?p=69625"},"modified":"2026-07-08T15:05:18","modified_gmt":"2026-07-08T07:05:18","slug":"sino-biopharmaceutical-secures-2-1b-astrazeneca-deal-for-inhaled-dual-pde3-4-inhibitor-tqc3721","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69625","title":{"rendered":"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sino Biopharmaceutical Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1177:HKG\">HKG: 1177<\/a>) announced that its subsidiary, <strong>Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd.<\/strong> (CTTQ), has entered into an <strong>exclusive global license agreement<\/strong> with <strong>AstraZeneca<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>) for <strong>TQC3721<\/strong>, a <strong>best-in-class inhaled dual PDE3\/4 inhibitor<\/strong> for respiratory diseases. The deal includes <strong>$200 million upfront<\/strong> and up to <strong>$1.9 billion in milestones<\/strong>, plus <strong>double-digit tiered royalties<\/strong> on global net sales.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-terms\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Sino Biopharmaceutical (via CTTQ) \/ AstraZeneca<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>TQC3721 (inhaled dual PDE3\/4 inhibitor)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Ex-China development\/commercialization + Global program rights<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>USD 200 million<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Up to USD 1.9 billion (development, regulatory, sales)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered double-digit percentage on annual net sales<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>USD 2.1 billion<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>8 July 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-therapeutic-differentiation\" class=\"wp-block-heading\">Product Profile &amp; Therapeutic Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual PDE3\/4 Inhibition<\/strong>: TQC3721 achieves <strong>balanced inhibition<\/strong> of both PDE3 (bronchodilation) and PDE4 (anti-inflammation), creating a <strong>synergistic therapeutic effect<\/strong> that addresses multiple pathological pathways in chronic respiratory diseases simultaneously.<\/li>\n\n\n\n<li><strong>Best-in-Class Potential<\/strong>: The molecule demonstrates superior efficacy and safety profiles compared to single-target PDE inhibitors and existing standard-of-care therapies across multiple respiratory indications including COPD and asthma.<\/li>\n\n\n\n<li><strong>Innovative Formulations<\/strong>: Developed as both a <strong>nebulized inhalation suspension<\/strong> and <strong>dry powder inhaler (DPI)<\/strong>, with the DPI formulation currently in <strong>Phase II clinical trials<\/strong>, positioning TQC3721 to become <strong>China&#8217;s first approved domestic inhaled dual PDE3\/4 inhibitor<\/strong>.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Chronic respiratory diseases affect over <strong>400 million people globally<\/strong>, with COPD alone representing a <strong>$15+ billion market<\/strong> and significant unmet need for therapies that can reduce exacerbations while improving lung function and quality of life.<\/p>\n\n\n\n<h2 id=\"h-development-status-amp-clinical-strategy\" class=\"wp-block-heading\">Development Status &amp; Clinical Strategy<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Current Stage<\/strong>: DPI formulation advanced to <strong>Phase II clinical trials<\/strong>, demonstrating proof-of-concept for efficacy and safety in target patient populations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Therapeutic Benefits<\/strong>: TQC3721 is designed to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Improve lung function through dual bronchodilatory mechanisms<\/li>\n\n\n\n<li>Reduce risk of acute exacerbations via anti-inflammatory effects<\/li>\n\n\n\n<li>Alleviate long-term disease burden through comprehensive pathway modulation<\/li>\n\n\n\n<li>Enhance patient compliance through convenient once-daily dosing<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Regulatory Pathway<\/strong>: The Phase II data will inform Phase III trial design and potential expedited regulatory pathways based on the molecule&#8217;s differentiated mechanism and clinical profile.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications-amp-market-impact\" class=\"wp-block-heading\">Strategic Implications &amp; Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Validation Milestone<\/strong>: The <strong>$2.1 billion deal value<\/strong> represents one of the largest out-licensing transactions for a Chinese biopharmaceutical company, validating both TQC3721&#8217;s clinical potential and China&#8217;s innovation capabilities in respiratory therapeutics.<\/li>\n\n\n\n<li><strong>Global Commercial Engine<\/strong>: AstraZeneca&#8217;s established <strong>respiratory franchise<\/strong> and global commercial infrastructure provide optimal conditions for maximizing TQC3721&#8217;s worldwide market potential, particularly given the company&#8217;s leadership in inhaled therapies.<\/li>\n\n\n\n<li><strong>Platform Technology<\/strong>: Success with TQC3721 could establish CTTQ&#8217;s <strong>inhaled drug delivery platform<\/strong> as a valuable asset for future respiratory pipeline candidates and additional partnership opportunities.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking information regarding licensing agreements, clinical development, and financial arrangements. Actual results may differ due to clinical trial outcomes, regulatory decisions, competitive dynamics, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070800004_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026070800004_c.\"><\/object><a id=\"wp-block-file--media-271a5861-5bd5-41dd-8cf0-fe506ded0b10\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070800004_c.pdf\">2026070800004_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026070800004_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-271a5861-5bd5-41dd-8cf0-fe506ded0b10\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co.,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[130,661,908,4621,313],"class_list":["post-69625","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-astrazeneca","tag-chia-tai-tianqing-pharmaceutical","tag-hkg-1177","tag-nyse-azn","tag-sino-biopharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has entered into an exclusive global license agreement with AstraZeneca (NYSE: AZN) for TQC3721, a best-in-class inhaled dual PDE3\/4 inhibitor for respiratory diseases. The deal includes $200 million upfront and up to $1.9 billion in milestones, plus double-digit tiered royalties on global net sales.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69625\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721\" \/>\n<meta property=\"og:description\" content=\"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has entered into an exclusive global license agreement with AstraZeneca (NYSE: AZN) for TQC3721, a best-in-class inhaled dual PDE3\/4 inhibitor for respiratory diseases. The deal includes $200 million upfront and up to $1.9 billion in milestones, plus double-digit tiered royalties on global net sales.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69625\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-08T07:05:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69625#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69625\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\\\/4 Inhibitor TQC3721\",\"datePublished\":\"2026-07-08T07:05:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69625\"},\"wordCount\":476,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"Chia Tai Tianqing Pharmaceutical\",\"HKG: 1177\",\"NYSE:\u202fAZN\",\"Sino Biopharmaceutical\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69625#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69625\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69625\",\"name\":\"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\\\/4 Inhibitor TQC3721 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-08T07:05:18+00:00\",\"description\":\"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has entered into an exclusive global license agreement with AstraZeneca (NYSE: AZN) for TQC3721, a best-in-class inhaled dual PDE3\\\/4 inhibitor for respiratory diseases. The deal includes $200 million upfront and up to $1.9 billion in milestones, plus double-digit tiered royalties on global net sales.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69625#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69625\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69625#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\\\/4 Inhibitor TQC3721\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721 - Insight, China&#039;s Pharmaceutical Industry","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has entered into an exclusive global license agreement with AstraZeneca (NYSE: AZN) for TQC3721, a best-in-class inhaled dual PDE3\/4 inhibitor for respiratory diseases. The deal includes $200 million upfront and up to $1.9 billion in milestones, plus double-digit tiered royalties on global net sales.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69625","og_locale":"en_US","og_type":"article","og_title":"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721","og_description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has entered into an exclusive global license agreement with AstraZeneca (NYSE: AZN) for TQC3721, a best-in-class inhaled dual PDE3\/4 inhibitor for respiratory diseases. The deal includes $200 million upfront and up to $1.9 billion in milestones, plus double-digit tiered royalties on global net sales.","og_url":"https:\/\/flcube.com\/?p=69625","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-08T07:05:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69625#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69625"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721","datePublished":"2026-07-08T07:05:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69625"},"wordCount":476,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","Chia Tai Tianqing Pharmaceutical","HKG: 1177","NYSE:\u202fAZN","Sino Biopharmaceutical"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69625#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69625","url":"https:\/\/flcube.com\/?p=69625","name":"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-08T07:05:18+00:00","description":"Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary, Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), has entered into an exclusive global license agreement with AstraZeneca (NYSE: AZN) for TQC3721, a best-in-class inhaled dual PDE3\/4 inhibitor for respiratory diseases. The deal includes $200 million upfront and up to $1.9 billion in milestones, plus double-digit tiered royalties on global net sales.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69625#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69625"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69625#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sino Biopharmaceutical Secures $2.1B AstraZeneca Deal for Inhaled Dual PDE3\/4 Inhibitor TQC3721"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69625","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69625"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69625\/revisions"}],"predecessor-version":[{"id":69627,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69625\/revisions\/69627"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69625"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69625"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69625"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}